ArticleInfection and drug resistance2026
Impact of Enhanced Infection Control Measures on Hospital-Acquired Carbapenem-Resistant
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sustainability and Impact of an Antimicrobial Stewardship Program on Broad-Spectrum Antibiotic Consumption in South Korea: A 14-Month Extended Follow-Up Study.Antibiotics (Basel, Switzerland) · 2026Article
- A retrospective analysis of pathogen distribution and antimicrobial resistance trends of bacteria in a tertiary hospital in China, 2021-2025.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant organisms (CROs) represent a major cause of healthcare-acquired infections. This study aims to evaluate the impact of enhanced infection control measures on the incidence of hospital-acquired carbapenem-resistant Methods: This study was conducted at a tertiary hospital in China. The baseline period (Period 1) spanned from January 1, 2022, to December 31, 2023. Starting January 1, 2024, an enhanced intervention (Period 2) was implemented, comprising weekly active surveillance for CROs, coupled with immediate notification and on-site audit with feedback to ensure prompt implementation of contact isolation for positive cases. The study compared the trends of CROs, incidence rates of hospital-acquired CROs infections, contact isolation order compliance rates, and the consumption intensity of carbapenems between the two periods. An interrupted time-series analysis was used to assess the intervention effect. Results: The incidence of CROs increased by 0.101 cases per 1000 patient-days per quarter in period 1 (95% CI: 0.006-0.209, Conclusion: Enhanced infection control measures were associated with a reduction in hospital-acquired CROs infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.